Open AccessSerum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome
Author(s) -
Héctor F. EscobarMorreale,
José I. BotellaCarretero,
M. Ángeles MartínezGarcía,
Manuel LuqueRamírez,
Francisco ÁlvarezBlasco,
José L. San Millán
Publication year - 2008
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje-08-0107
Subject(s) - osteoprotegerin , medicine , endocrinology , polycystic ovary , rankl , body mass index , obesity , receptor , insulin resistance , activator (genetics)
Osteoprotegerin (OPG), an inhibitor of osteoclastic bone resorption, has a variety of functions including anti-inflammatory effects and a possible cardiovascular protective role. Both low-grade chronic inflammation and cardiovascular risk are increased in women with the polycystic ovary syndrome (PCOS). We aimed to study serum OPG concentrations in PCOS patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom